Loading...
XSTOBINV
Market cap230mUSD
Dec 23, Last price  
38.90SEK
1D
0.00%
1Q
-13.65%
Jan 2017
-48.27%
Name

BioInvent International AB

Chart & Performance

D1W1MN
XSTO:BINV chart
P/E
P/S
35.82
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
36.63%
Rev. gr., 5y
13.14%
Revenues
71m
-78.09%
58,747,00028,198,00050,829,000143,437,000252,138,00080,659,00082,866,000124,649,00042,946,00081,713,00046,932,00015,925,00071,284,00045,014,00038,548,00093,740,000147,372,00019,384,000326,126,00071,461,000
Net income
-330m
L+869.06%
-92,516,000-139,862,000-108,833,000-16,093,00016,251,000-176,661,000-128,400,000-67,053,000-187,845,000-18,039,000-53,985,000-90,681,000-62,587,000-100,528,000-123,163,000-139,115,000-76,669,000-278,961,000-34,085,000-330,304,000
CFO
-342m
L+728.80%
-88,744,000-105,479,000-101,228,00012,627,00043,726,000-127,143,000-117,700,000-55,454,000-170,381,000-54,652,000-76,028,000-72,573,000-72,049,000-75,876,000-141,394,000-125,427,000-62,622,000-245,843,000-41,227,000-341,691,000
Earnings
Feb 20, 2025

Profile

BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells; partnership and collaboration with Transgene to co-develskylinop multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck for the clinical development of BI-1808. The Company was incorporated in 1996 and is based in Lund, Sweden.
IPO date
Jun 12, 2001
Employees
103
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
71,461
-78.09%
326,126
1,582.45%
19,384
-86.85%
Cost of revenue
442,040
376,679
297,775
Unusual Expense (Income)
NOPBT
(370,579)
(50,553)
(278,391)
NOPBT Margin
Operating Taxes
204
(8,418)
517
Tax Rate
NOPAT
(370,783)
(42,135)
(278,908)
Net income
(330,304)
869.06%
(34,085)
-87.78%
(278,961)
263.85%
Dividends
Dividend yield
Proceeds from repurchase of equity
30,959
279,849
900,794
BB yield
-2.48%
-14.19%
-36.00%
Debt
Debt current
8,709
8,190
6,835
Long-term debt
37,779
45,736
49,899
Deferred revenue
Other long-term liabilities
Net debt
(427,312)
(1,037,261)
(1,136,229)
Cash flow
Cash from operating activities
(341,691)
(41,227)
(245,843)
CAPEX
(13,304)
(12,377)
(13,260)
Cash from investing activities
59,681
(628,848)
(467,542)
Cash from financing activities
23,139
273,487
894,870
FCF
(371,434)
(45,063)
(298,396)
Balance
Cash
1,068,699
1,017,481
1,082,829
Long term investments
(594,899)
73,706
110,134
Excess cash
470,227
1,074,881
1,191,994
Stockholders' equity
(2,449,529)
(2,122,342)
(2,082,928)
Invested Capital
3,782,500
3,755,427
3,478,282
ROIC
ROCE
EV
Common stock shares outstanding
65,798
61,521
54,161
Price
18.96
-40.84%
32.05
-30.63%
46.20
0.65%
Market cap
1,247,523
-36.73%
1,971,748
-21.20%
2,502,238
89.84%
EV
820,211
934,487
1,366,009
EBITDA
(353,824)
(35,829)
(263,781)
EV/EBITDA
Interest
638
650
517
Interest/NOPBT